Cinkate Medicine Chemical Intermediate (Shanghai) Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) for CNY 33 million on January 31, 2023. For the year ended, December 31, 2022, Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. total asset is CNY 465.30 million and net asset is CNY 94.54 million. The transaction was approved by Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. the first session of the 10th directorate.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.94 CNY | -0.55% | -3.78% | +33.09% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.09% | 1.07B | |
+32.29% | 694B | |
+29.39% | 593B | |
-1.58% | 371B | |
+19.94% | 331B | |
+7.29% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.73% | 169B |
- Stock Market
- Equities
- 600200 Stock
- News JiangSu WuZhong Pharmaceutical Development Co., Ltd.
- Cinkate Medicine Chemical Intermediate Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. for CNY 33 million.